Oral Semaglutide in Patients With Alzheimer's Disease

NCT07200622 on ClinicalTrials.gov · last registry update 2025-10-01

Registered but not yet open, with 60 participants planned. Due to report 31 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: To evaluate the safety and tolerability of oral semaglutide in an AD population. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Imperial College London
Sponsor type: Other
Enrollment: 60
Started: 2025-09-25
Primary completion: 2027-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To evaluate the safety and tolerability of oral semaglutide in an AD population.

Conditions studied

Alzheimer Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.